Compositions for the inhibition of giardia lamblia

Abstract

The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

1 - 14 . (canceled) 
     
     
         15 . A method of treating and/or reducing the development of giardiasis in a subject, comprising administering a composition exhibiting a bile-salt hydrolase activity to a subject;
 wherein the composition is chosen from:   a composition comprising at least one bile-salt hydrolase (BSH) enzyme, wherein the BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6;   a composition comprising a lactic acid bacterium able to secrete at least one BSH enzyme, wherein the BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6, and wherein the lactic acid bacterium is not  Lactobacillus johnsonii  La1,  Lactobacillus acidophilus, Bifidobacterium bifidum  or  Bifidobacterium infantis ; and   a combination thereof.   
     
     
         16 . The method of  claim 15 , wherein the administered composition comprises at least one bile-salt hydrolase (BSH) enzyme having an amino acid sequence at least 95% identical to SEQ ID NO: 6. 
     
     
         17 . The method of  claim 16 , wherein the BSH enzyme has the amino acid sequence of SEQ ID NO: 6. 
     
     
         18 . The method of  claim 16 , wherein the subject is infected with  Giardia.    
     
     
         19 . The method of  claim 16 , wherein the subject is not infected with  Giardia.    
     
     
         20 . The method of  claim 16 , wherein the subject is a human being or an animal. 
     
     
         21 . The method of  claim 15 , wherein the administered composition comprises a lactic acid bacterium able to secrete at least one BSH enzyme, wherein the BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6, and wherein the lactic acid bacterium is not  Lactobacillus johnsonii  La1 , Lactobacillus acidophilus, Bifidobacterium bifidum  or  Bifidobacterium infantis.    
     
     
         22 . The method of  claim 21 , wherein the BSH enzyme has the amino acid sequence of SEQ ID NO: 6. 
     
     
         23 . The method of  claim 21 , wherein the subject is infected with  Giardia.    
     
     
         24 . The method of  claim 21 , wherein the subject is not infected with  Giardia.    
     
     
         25 . The method of  claim 21 , wherein the subject is a human being or an animal. 
     
     
         26 . The method of  claim 21 , wherein the lactic acid bacterium able to secrete at least one BSH enzyme is selected from:
   Lactobacillus , but not  Lactobacillus johnsonii  La1 or  Lactobacillus acidophilus ; and     Bifidobacterium , but not  Bifidobacterium bifidum  or  Bifidobacterium infantis.      
     
     
         27 . The method according to  claim 26 , wherein the lactic acid bacterium is a  Lactobacillus  chosen from the group consisting of:
   Lactobacillus johnsonii , but not  Lactobacillus johnsonii  La1;     Lactobacillus gasseri;        Lactobacillus acidophilus , but not  Lactobacillus acidophilus  La10; and     Lactobacillus reuteri.      
     
     
         28 . A method of treating or reducing the development of giardiasis in a subject, comprising administering a composition exhibiting a bile-salt hydrolase activity to a subject;
 wherein said composition comprises a lactic acid bacterium able to secrete at least one BSH enzyme, and wherein said lactic acid bacterium is not  Lactobacillus johnsonii  La1,  Lactobacillus acidophilus, Bifidobacterium bifidum  or  Bifidobacterium infantis;      wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.   
     
     
         29 . The method of  claim 28 , wherein the subject is infected with  Giardia.    
     
     
         30 . The method of  claim 28 , wherein the subject is not infected with  Giardia.    
     
     
         31 . The method according to any  claim 28 , wherein said BSH enzyme comprises an amino acid sequence having at least 95% identity with an amino acid sequence chosen from the group consisting of:  Lactobacillus johnsonii  La1 BSH-12 (SEQ ID NO: 1),  Lactobacillus johnsonii  La1 BSH-47 (SEQ ID NO: 2),  Lactobacillus johnsonii  La1 BSH-56 (SEQ ID NO: 3),  Lactobacillus gasseri  BSH-A (SEQ ID NO: 4),  Lactobacillus gasseri  BSH-B (SEQ ID NO: 5),  Lactobacillus johnsonii  DPC 6026 BSH (SEQ ID NO: 6),  Lactobacillus johnsonii  DPC 6026 BSH (SEQ ID NO: 7), and  Lactobacillus johnsonii  DPC 6026 BSH (SEQ ID NO: 8). 
     
     
         32 . The method according to  claim 28 , wherein said administered composition comprises a lactic acid bacterium able to secrete a BSH, wherein said bacterium is selected from:
   Lactobacillus , but not  Lactobacillus johnsonii  La1 or  Lactobacillus acidophilus ; and     Bifidobacterium , but not  Bifidobacterium bifidum  or  Bifidobacterium infantis.      
     
     
         33 . The method according to  claim 28 , wherein said lactic acid bacterium is a  Lactobacillus  chosen from the group consisting of:
   Lactobacillus johnsonii , but not  Lactobacillus johnsonii  La1;     Lactobacillus gasseri ; and     Lactobacillus acidophilus , but not  Lactobacillus acidophilus  La10; and     Lactobacillus reuteri.      
     
     
         34 . The method according to  claim 28 , wherein the subject is a human being or an animal.